Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-10T12:13:14.553Z Has data issue: false hasContentIssue false

Which antidepressant agent can be used in patients receiving tamoxifen?

Published online by Cambridge University Press:  13 August 2021

A. Maamri
Affiliation:
Faculty Of Medincine Of Tunis, RAZI HOSPITAL, TUNIS, Tunisia Psychiatry, Outpatient Service, Razi Hospital, Manouba, Tunisia
H. Ghabi*
Affiliation:
Outpatients Ward Of Psychiatry, Razi hospital, Manouba, Tunisia
H. Zalila
Affiliation:
Faculty Of Medincine Of Tunis, RAZI HOSPITAL, TUNIS, Tunisia Psychiatry, Outpatient Service, Razi Hospital, Manouba, Tunisia Outpatients Ward Of Psychiatry, Razi hospital, Manouba, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression is frequently observed in carcinology. Many patients with breast cancer, receiving Tamoxifen, may need antidepressants to treat depression. Tamoxifen is a synthetic non-steroidal antioestrogen metabolized by the cytochrome P450 2D6(CYP2D6) to endoxifen which is the active metabolite of this drug. It was reported that the concomitant prescription of Tamoxifen and some antidepressant agents such as paroxetine and fluoxetine may decrease the anticancer effect of tamoxifen as they may inhibit the CYP2D6 pathway.

Objectives

The objective of this case was to highlight the particularity of management of depression in patients under tamoxifen.

Methods

Case report description of a patient treated with Tamoxifen for her breast cancer and who was admitted for major depression, followed by a literature review.

Results

A 36 –year- old woman, had breast cancer and she underwent a mastectomy followed by chemotherapy. Since September 2016, she received 20 mg per day of Tamoxifen as an antihormonal treatment. In November 2018, she was referred to our psychiatry department for depressive symptoms. The patient was sad, she reported social withdrawal, insomnia, anhedonia, and low self-esteem. She had no history of mania or hypomania. A major depressive episode was diagnosed. We prescribed Escitalopram 10 mg per day with clinical improvement. The psychiatric and oncologic status of the patient was stable after two years under tamoxifen and Escitalopram.

Conclusions

The choice of the adequate antidepressant agent in patients under Tamoxifen remains a challenge and requires a thorough knowledge of drug interactions.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.